KR20230154194A - 신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제 - Google Patents

신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제 Download PDF

Info

Publication number
KR20230154194A
KR20230154194A KR1020237030728A KR20237030728A KR20230154194A KR 20230154194 A KR20230154194 A KR 20230154194A KR 1020237030728 A KR1020237030728 A KR 1020237030728A KR 20237030728 A KR20237030728 A KR 20237030728A KR 20230154194 A KR20230154194 A KR 20230154194A
Authority
KR
South Korea
Prior art keywords
water
hco
mmol
conditions
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237030728A
Other languages
English (en)
Korean (ko)
Inventor
리차드 티. 베레시스
존 치지앙 히
경 이
Original Assignee
이칸 스쿨 오브 메디슨 엣 마운트 시나이
더 유나이티드 스테이츠 거번먼트 애즈 리프리젠티드 바이 더 디파트먼트 오브 베테랑스 어페어즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이칸 스쿨 오브 메디슨 엣 마운트 시나이, 더 유나이티드 스테이츠 거번먼트 애즈 리프리젠티드 바이 더 디파트먼트 오브 베테랑스 어페어즈 filed Critical 이칸 스쿨 오브 메디슨 엣 마운트 시나이
Publication of KR20230154194A publication Critical patent/KR20230154194A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020237030728A 2021-02-10 2022-02-09 신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제 Pending KR20230154194A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147859P 2021-02-10 2021-02-10
US63/147,859 2021-02-10
PCT/US2022/015767 WO2022173795A1 (en) 2021-02-10 2022-02-09 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS

Publications (1)

Publication Number Publication Date
KR20230154194A true KR20230154194A (ko) 2023-11-07

Family

ID=82837244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237030728A Pending KR20230154194A (ko) 2021-02-10 2022-02-09 신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제

Country Status (9)

Country Link
US (1) US20250179084A1 (https=)
EP (1) EP4291183B1 (https=)
JP (1) JP2024506387A (https=)
KR (1) KR20230154194A (https=)
CN (1) CN117479934A (https=)
AU (1) AU2022221336A1 (https=)
CA (1) CA3210658A1 (https=)
MX (1) MX2023009323A (https=)
WO (1) WO2022173795A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240051965A1 (en) * 2022-08-05 2024-02-15 Icahn School Of Medicine At Mount Sinai Oxygen-containing heterocyclic compound and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2069335T3 (pl) * 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
PE20091339A1 (es) * 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2210890A1 (en) * 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
ES2907624T3 (es) * 2017-01-06 2022-04-25 Icahn School Med Mount Sinai Inhibidores de oxadiazol de HIPK2 para el tratamiento de la fibrosis renal
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド Ｓ１ｐ１活性を調節するための化合物およびその使用法

Also Published As

Publication number Publication date
MX2023009323A (es) 2023-12-14
WO2022173795A1 (en) 2022-08-18
US20250179084A1 (en) 2025-06-05
CN117479934A (zh) 2024-01-30
JP2024506387A (ja) 2024-02-13
EP4291183A1 (en) 2023-12-20
AU2022221336A1 (en) 2023-08-24
EP4291183B1 (en) 2026-04-08
EP4291183A4 (en) 2025-01-08
CA3210658A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
KR102866499B1 (ko) Tead 전사인자의 신규한 소분자 저해제
EP3310767B1 (en) 2,5-disubstituted benzoxazole and benzothiazole compounds as nadph oxidase 4 inhibitors
AU2021376500B2 (en) Application of isoquinoline compound in tumor treatment
CN116332938A (zh) 稠合三环类衍生物及其制备方法和用途
KR101335746B1 (ko) 이치환된 프탈라진 헷지호그 경로 길항제
AU2015270125B2 (en) Naphthyridinedione derivatives
CN116120296A (zh) 一种多环化合物、包含其的药物组合物、其制备方法及其用途
JP2013507419A (ja) ヒストンデアセチラーゼ阻害剤としてのスピロ環誘導体
EP3406612B1 (en) Carboline derivative serving as bromodomain inhibitor
KR20220140731A (ko) 키나아제 억제제로 작용하는 다환성 화합물
CN119365474A (zh) Stat3抑制剂的前药
KR20230154194A (ko) 신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제
CN116507618B (zh) 一种螺环类化合物、包含其药物组合物及其应用
CN115974855A (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
CN111848572A (zh) 酰胺类化合物及其制备方法和用途
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
RU2782469C2 (ru) Апоптоз-индуцирующие агенты
CN121419769A (zh) 异双功能化合物及其使用方法
CN120289361A (zh) 喹诺酮类化合物及其制备方法和抗衰老用途
CN116063296A (zh) 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN120192310A (zh) 作为ripk1抑制剂的苯并氧氮杂卓化合物
HK40029944B (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40029944A (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250204

Comment text: Request for Examination of Application